
1. Technology overview
Primaa is a Paris-based medtech company founded in 2018 that develops AI software for automated cancer diagnosis on digital pathology slides. It addresses the shortage of pathologists and the time needed to review histology cases.
Cleo Breast detects and quantifies breast cancer biomarkers such as mitoses and invasive carcinoma, and Cleo Skin supports dermatopathology for skin cancers. The software uses deep learning image analysis and a smart worklist for triage and case prioritisation. Cleo Skin received CE marking under the IVDR in March 2026. Users in France include Institut Curie, AP-HP and Saint-Joseph Hospital.
2. Highlighted features & specifications
- Breast cancer analysis: Cleo Breast detects mitoses and invasive carcinoma and quantifies biomarkers.
- Micrometastasis detection: Cleo Breast received CE-IVDR marking for this use in September 2026.
- Dermatopathology: Cleo Skin supports diagnosis of melanoma and skin carcinomas on slides.
- Smart worklist: triage and prioritisation of cases.
- Scanner and viewer integration: workflow integration with PathPresenter announced September 2026.
- Scientific evidence: peer-reviewed studies published on the website.
3. Potential application
Large oncology hospitals in Vietnam could pilot breast cancer slide triage to shorten reporting time. Private pathology laboratories with slide scanners could add AI second reads. Teaching hospitals could use it for pathologist training and quality assurance.
4. Benefits
Supports pathologists with automated biomarker detection and quantification, which the company links to faster case review and higher diagnostic confidence. A smart worklist prioritises cases. CE-IVDR marking on Cleo Breast and Cleo Skin gives European labs a certified route to deploy AI in diagnostic workflows.
5. Market trends & opportunities
Digital pathology adoption is growing as pathologist shortages and rising cancer caseloads increase demand for AI-assisted slide review. Vietnam has few pathologists relative to cancer incidence, and large oncology hospitals are starting to digitise slide scanning.
6. Other information
Founded in 2018, address 10 rue Bachaumont, Paris. Raised 7M EUR in October 2025 (Tech.eu). Cleo Skin CE-IVDR in March 2026 and Cleo Breast micrometastasis CE-IVDR in September 2026. Partners listed include AP-HP, Sectra, Unilabs, PathAI and Proscia.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































